Related Experiment Video

Updated: Apr 5, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Myeloma Propagating Cells, Drug Resistance and Relapse

Anastasios Karadimitris1,2, Aristeidis Chaidos1,2, Valentina Caputo1

  • 1Centre for Haematology, Department of Medicine, Imperial College London, London, United Kingdom.

Stem Cells (Dayton, Ohio)
|August 26, 2015
PubMed

Insights

Multiple myeloma (MM) research identifies cells with myeloma-propagating activity (MMPA) linked to disease relapse and drug resistance. New strategies aim to characterize these cells for better MM treatment and patient survival.

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Multiple myeloma (MM) is an incurable plasma cell malignancy.
  • Understanding the cells driving MM (myeloma-propagating activity, MMPA) is crucial for improving outcomes.
  • Current knowledge of MM genetics lacks a complete picture of MMPA's biological role.

Purpose of the Study:

  • To review recent findings on MMPA in multiple myeloma.
  • To explore the link between MMPA, cellular hierarchy, drug resistance, and relapse.
  • To propose a framework for dissecting MMPA properties using advanced technologies.

Main Methods:

  • Review of recent scientific literature on multiple myeloma and MMPA.
  • Analysis of data linking MMPA to myeloma clonotypic populations and disease progression.
  • Conceptual framework development integrating genomics and phenomics.

Main Results:

  • MMPA is associated with myeloma clonotypic populations organized in a hierarchy similar to normal B cell development.
  • MMPA is linked to drug resistance and disease relapse in multiple myeloma.
  • Recent technological advances offer new possibilities for MMPA characterization.

Conclusions:

  • Dissecting the cellular and molecular properties of MMPA is essential for understanding MM.
  • An integrated, patient-specific approach using genomics and phenomics is proposed.
  • These strategies hold promise for improving MM disease control, survival, and potential cure.
Keywords:
B lymphocytesCancerCancer stem cellsEpigeneticsFlow cytometryHematologic malignanciesStem cell plasticityXenotransplantation

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.9K